Chemotherapy-related cognitive dysfunction in breast cancer

Seminars in Oncology Nursing

Volumn 19, Issue SUPPL. 2, 2003, Pages 17-24

  O'Shaughnessy, Joyce ^a,b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; THIOTEPA; ANTINEOPLASTIC AGENT;

ANEMIA; ANXIETY DISORDER; ASTHENIA; BRAIN FUNCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CAREGIVER; COGNITIVE DEFECT; DEPRESSION; ESTROGEN THERAPY; FATIGUE; HEALTH CARE; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL RESEARCH; NURSE; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; ONCOLOGY NURSING; PATIENT EDUCATION; STANDARD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; NURSE'S ROLE; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; ONCOLOGIC NURSING; PATIENT EDUCATION; QUALITY OF LIFE;

EID: 85047694124     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2003.09.002     Document Type: Article

References (53)

1. Olin JJ: Cognitive function after systemic therapy for breast cancer. Oncology 15:613-618, 2001
2. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002
3. Brezden CB, Phillips K, Abdolell M, et al: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701, 2000
4. O'Shaughnessy JA: Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3:8116-8120, 2002 (suppl 3)
5. Schagen SB, van Dam FSAM, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999
6. Schagen SB, Muller MJ, Boogerd W, van Dam FSAM: Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clin Breast Cancer 3:8100-8108, 2002 (suppl 3)
7. van Dam FSAM, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998
8. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61-66, 1995
9. Phillips KA, Bernhard J: Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 95:190-197, 2003
10. Bender CM, Paraska KK, Sereika SM, et al: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manage 21:407-424, 2001
11. Ahles TA, Saykin AJ: Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3:S84-S90, 2002 (suppl 3)
12. Armstrong T, Rust D, Kohtz JR: Neurologic, pulmonary, and cutaneous toxicities of high-dose chemotherapy. Oncol Nurs Forum 24:23-33, 1997 (suppl 1)
13. Schagen SB, Muller MJ, Boogerd W, et al: Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 13:1387-1397, 2002
14. Beard GM, Kokmen E, O'Brien PG, et al: Risk of Alzheimer's disease among elderly patients with anemia: Population-based investigations in Olmsted County, Minnesota. Ann Epidemiol 7:219-224, 1997
15. Milward EA, Grayson DA, Greasey H, et al: Evidence for association of anaemia with vascular dementia. Neuroreport 10:2377-2381, 1999
16. Jacobsen PB, Thors CL, Cawley M, et al: Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. Proc Am Soc Clin Oncol 21:386a, 2002 (abstr)
17. Tchen N, Juffs H, Yi Q-L, et al: Fatigue, menopausal symptoms and their interaction in 100 women receiving adjuvant chemotherapy and 100 age-matched controls: Results of a prospective cohort study. Proc Am Soc Clin Oncol 21:388a, 2002 (abstr)
18. Haskell SG, Richardson ED, Horwitz RI: The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature. J Clin Epidemiol 50:1249-1264, 1997
19. Vassilopoulou-Sellin R, Zolinski G: Estrogen replacement therapy in women with breast cancer: A survey of patient attitudes. Am J Med Sci 304:145-149, 1992
20. Robinson D, Friedman L, Marcus R, et al: Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 42:919-922, 1994
21. Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17:485-495, 1992
22. Henderson VW, Paganini-Hill A, Emanuel CK, et al: Estrogen replacement therapy in older women. Arch Neurol 51:896-900, 1994
23. Thai LJ, Thomas RG, Mulnard R, et al: Estrogen levels do not correlate with improvement in cognition. Arch Neurol 60:209-212, 2003
24. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854, 2003
25. Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 28:7-14, 2001 (suppl 8)
26. Marsh JT, Brown WS, Wolcott D, et al: rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39:155-163, 1991
27. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360, 2000
28. Vogelzang NJ, Breitbart W, Cella D, et al: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol 34:4-12, 1997 (suppl 2)
29. Messias DKH, Yeager KA, Dibble SL, et al: Patients' perspectives of fatigue while undergoing chemotherapy. Oncol Nurs Forum 24:43-48, 1997
30. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12:189-198, 1975
31. Jacobs JW, Bernhard MR, Delgado A, et al: Screening for organic mental syndromes in the medically ill. Ann Intern Med 86:40-46, 1977
32. Cimprich B: Symptom management: Loss of concentration. Semin Oncol Nurs 11:279-288, 1995
33. McQuellon RP: In review of: Olin JJ: Cognitive function after systemic therapy for breast cancer. Oncology 15:618, 621, 2001
34. Freeman JR, Broshek DK: Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer 3:S91-S99, 2002 (suppl 3)
35. Cimprich B: Attentional fatigue following breast cancer surgery. Res Nurs Health 15:199-207, 1992
36. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: The executive interview. J Am Geriatr Soc 40:1221-1226, 1992
37. Furuhjelm M, Fedor-Freybergh P: The influence of estrogens on the psyche in climacteric and post-menopausal women, in Van Keep PA, Greenblatt RB, Albeaux-Fernet MM, (eds): Consensus on Menopause Research. Baltimore, MD, University Park Press, 1976, pp pp 84-93
38. Barrett-Connor E, Kritz-Silverstein D: Estrogen replacement therapy and cognitive function in older women. JAMA 269:2637-2641, 1993
39. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333, 2002
40. Glaspy J, Bukowski R, Steinberg D, et al, for the Procrit Study Group: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
41. Demetri GD, Kris M, Wade J, et al, for the Procrit Study Group: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
42. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
43. Littlewood TJ, Bajetta E, Nortier JWR, et al, for the Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
44. Crawford D, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895, 2002
45. Hudis C, Williams D, Gralow J, et al: Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during adjuvant chemotherapy. Proc Am Soc Clin Oncol 21:380a, 2002 (abstr)
46. Buemi M, Cavallaro E, Floccari F, et al: Erythropoietin and the brain: From neurodevelopment to neuroprotection. Clin Sci 103:275-282, 2002
47. Brines ML, Ghezzi P, Keenan S, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000
48. Cerami A: Beyond erythropoiesis: Novel applications for recombinant human erythropoietin. Semin Hematol 38:33-39, 2001 (suppl 7)
49. Celik M, Gökmen N, Erbayraktar S, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci 99:2258-2263, 2002
50. Eid T, Brines M: Recombinant human erythropoietin for neuroprotection: What is the evidence? Clin Breast Cancer 3:8109-8115, 2002 (suppl 3)
51. Ehrenreich H, Hasselblatt M, Piotr L, et al: Erythropoietin treatment for acute stroke: A randomized double-blind proof-of-concept trial in man. Stroke 33:354, 2002 (abstr)
52. Royall DR, Cabello M, Polk MJ: Executive dyscontrol: An important factor affecting the level of care received by older retirees. J Am Geriatr Soc 46:1519-1524, 1998
53. O'Shaughnessy J, Vukelja S, Savin M, et al: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: Analysis of 6-month follow-up data. Breast Cancer Res Treat 76:8138, 2002 (abstr)